Leaflet LARTRUVO 10mg / ml concentrate for solution for infusion
Indicated for: cancer
Route of administration: infusion
Substance: olaratumab (monoclonal antibody)
ATC: L01XC27 (Antineoplastic and immunomodulating agents | Other antineoplastic agents | Monoclonal antibodies)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Olaratumab is a monoclonal antibody used for the treatment of advanced soft tissue sarcoma, in combination with doxorubicin. It works by blocking the platelet-derived growth factor receptor alpha (PDGFR-α), thereby inhibiting the growth and spread of cancer cells.
The medication is administered intravenously, as directed by your doctor, usually in treatment cycles. It is important to monitor side effects and undergo regular tests to assess the effectiveness of the treatment.
Side effects may include nausea, fatigue, neutropenia, injection site reactions, or, in rare cases, severe allergic reactions.
Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of olaratumab.
General data about LARTRUVO 10mg / ml
- Substance: olaratumab
- Date of latest medicines list: 01-07-2020
- Product code: W63494002
- Concentration: 10mg / ml
- Pharmaceutical form: concentrate for solution for infusion
- Quantity: 2
- Product type: Original
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.